investing and capital-raising in the life sciences industry. He currently serves as the Chief Executive Officer of Ascendancy Healthcare, Inc. From 2005 until mid-2011, Mr. Zweifach was a Partner at Reedland Capital Partners, a boutique investment bank, where he headed its life sciences M&A and advisory efforts. Prior to joining Reedland, he was the CEO of Pathways Diagnostics, a biomarker development company. From 1997 to 2004 he was a Managing Director/CFO of Bay City Capital. He received his BA in Biology from UC San Diego and holds an MS in Human Physiology from UC Davis.
"I am excited to welcome Sandy to the Anthera Board of Directors," said Dr. Christopher Henney , Ph.D., Anthera's Chairman of the Board. "His extensive expertise in commercial development and pharmaceutical transactions will be invaluable as we continue to move forward with the development of blisibimod."
About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 <
Page: 1 2 3 4 Related biology technology :1
|SOURCE Anthera Pharmaceuticals|
Copyright©2012 PR Newswire.
All rights reserved
. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update2
. Anthera to Report Second Quarter 2012 Financial Results3
. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results4
. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals5
. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference6
. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence7
. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies8
. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz9
. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California10
. AVANIR Pharmaceuticals To participate in two conferences in March11
. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013